Eli Lilly and Company: clinical-trial pipeline
Eli Lilly and Company is the sponsor of 2,092 clinical trials in ClinicalTrials.gov and the EU CTIS portal; 235 are not yet finished and 23 were first posted in the last 90 days. Source: Arcadium Data, data as of .
Open trials235
Phase 2/3 and 3561
Countries75
New in 90 days23
Trials by phase
| Phase | Trials |
|---|---|
| Phase 1 | 790 |
| Phase 3 | 543 |
| Phase 2 | 471 |
| Phase 4 | 174 |
| Phase 1/2 | 51 |
| Not applicable | 44 |
| Phase 2/3 | 18 |
| Early phase 1 | 1 |
Trials by status
| Status | Trials |
|---|---|
| Completed | 1,704 |
| Terminated | 130 |
| Recruiting | 112 |
| Active, not recruiting | 95 |
| Not yet recruiting | 28 |
| Withdrawn or not authorised | 22 |
| Suspended or halted | 1 |
Condition areas
| Area | Trials |
|---|---|
| Oncology | 539 |
| Metabolic and endocrine (diabetes, obesity) | 441 |
| Immunology and rheumatology | 174 |
| Psychiatry and mental health | 145 |
| Neurology | 141 |
| Nephrology and urology | 107 |
| Gastroenterology and liver | 97 |
| Musculoskeletal | 87 |
| Dermatology | 79 |
| Cardiovascular | 63 |
| Women's health and obstetrics | 63 |
| Rare and genetic diseases | 24 |
Countries
| Country | Trials |
|---|---|
| United States | 1,382 |
| Germany | 449 |
| Spain | 388 |
| Japan | 376 |
| Canada | 321 |
| France | 316 |
| United Kingdom | 293 |
| Italy | 285 |
| Puerto Rico | 278 |
| Poland | 275 |
| Mexico | 260 |
| Australia | 227 |
| Belgium | 225 |
| South Korea | 223 |
| Argentina | 215 |
Latest changes
| Day | Change | Trial |
|---|---|---|
| 2026-10-22 | New trial posted | A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesit… |
| 2026-10-20 | New trial posted | A Study of LY3873862 in Participants With Sporadic or Familial Amyotrophic Lateral Sclero… |
| 2026-10-20 | New trial posted | A Study of LY4167586 in Participants With Obesity or Overweight With or Without Type 2 Di… |
| 2026-10-19 | New trial posted | A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes |
| 2026-10-19 | New trial posted | A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes |
| 2026-10-15 | New trial posted | J3R-MC-YDAS: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate… |
| 2026-10-09 | New trial posted | A Study of LY4515100 in Healthy Male Participants |
| 2026-10-09 | New trial posted | A Study of Single and Multiple Doses of LY5625573 in Healthy Participants, Including Japa… |
| 2026-09-28 | New trial posted | A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (A… |
| 2026-09-24 | New trial posted | A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disea… |
| 2026-09-18 | New trial posted | A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and… |
| 2026-09-16 | New trial posted | A Study of Selpercatinib (LY3527723) in Participants With Rearranged During Transfection… |
Open trials
The 25 most recently changed open trials.
| Registry id | Title | Phase | Status | Countries |
|---|---|---|---|---|
| NCT02779751 | A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer | Phase 1 | Active, not recruiting | Belgium, Spain, France, Italy +2 |
| NCT04975308 | A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Par… | Phase 3 | Active, not recruiting | Argentina, Austria, Australia, Belgium +17 |
| 2023-506131-15-00 | I4V-MC-JAHX: A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Pati… | Phase 3 | Recruiting | Austria, Belgium, Czechia, Germany +5 |
| NCT03157128 | A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tum… | Phase 1/2 | Active, not recruiting | Australia, Canada, Switzerland, Germany +12 |
| NCT04188548 | A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer | Phase 1 | Active, not recruiting | Australia, Belgium, Spain, France +4 |
| 2023-506783-14-00 | J2G-MC-JZJC: LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Pl… | Phase 3 | Active, not recruiting | Belgium, Germany, Spain, France +3 |
| 2023-506782-56-00 | J2G-MC-JZJB: A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choic… | Phase 3 | Active, not recruiting | Belgium, Czechia, Germany, Spain +5 |
| 2023-506781-30-00 | I3Y-MC-JPBL: MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant with or… | Phase 3 | Active, not recruiting | Belgium, Spain, Greece, Italy +1 |
| NCT06238479 | A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors | Phase 1 | Active, not recruiting | Australia, Belgium, China, Spain +3 |
| NCT04819100 | A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) | Phase 3 | Not yet recruiting | Austria, Australia, Belgium, Brazil +27 |
| NCT03899792 | A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Ner… | Phase 1/2 | Active, not recruiting | Australia, Canada, Germany, Denmark +7 |
| NCT05307705 | A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors | Phase 1 | Active, not recruiting | Australia, Belgium, Canada, China +9 |
| NCT03906331 | J2G-OX-Y001 - A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advance… | Phase 4 | Active, not recruiting | Spain, France, Italy, Poland |
| NCT06338995 | A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With… | Phase 3 | Recruiting | Argentina, Belgium, Bulgaria, Canada +16 |
| NCT05509777 | A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease | Phase 3 | Recruiting | Austria, Belgium, Brazil, Canada +12 |
| NCT06413706 | A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With… | Phase 2 | Active, not recruiting | Australia, Belgium, Denmark, Spain +6 |
| NCT06339008 | A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1) | Phase 3 | Active, not recruiting | Belgium, China, Germany, South Korea +2 |
| NCT06400472 | A Study of Sofe-M in Participants With Selected Advanced Solid Tumors | Phase 1 | Recruiting | Australia, Spain, France, Italy +3 |
| NCT04106219 | A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma | Phase 1 | Active, not recruiting | Australia, Belgium, Germany, Spain +5 |
| NCT06465069 | A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors | Phase 1 | Recruiting | Australia, China, Spain, France +4 |
| 2023-507655-30-00 | I8F-MC-GPIX: Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for the Treatment of Obesity and W… | Phase 3 | Active, not recruiting | Germany, Spain, France |
| NCT06662383 | A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity | Phase 3 | Active, not recruiting | Argentina, Germany, Poland, Puerto Rico +1 |
| NCT04437511 | A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) | Phase 3 | Active, not recruiting | Australia, Canada, Czechia, United Kingdom +5 |
| NCT04956640 | Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | Phase 1/2 | Recruiting | Australia, Canada, France, Japan +2 |
| NCT04521686 | Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations | Phase 1 | Active, not recruiting | Australia, Spain, France, Hong Kong SAR China +5 |
Hiring for clinical development
Eli Lilly and Company has 49 open jobs with a clinical, regulatory, safety, biostatistics or medical-affairs title on its own career sites.
Website: lilly.com. All sponsors: clinical-trial pipeline by sponsor.
Track a sponsor's pipeline
The API returns the same trials by sponsor website, phase, status, condition and country with a change feed, joined to hiring and public contract awards. Try it without a key on one sponsor.
Sources: ClinicalTrials.gov (U.S. National Library of Medicine, public domain) and the EU Clinical Trials Information System public portal (European Medicines Agency), data as of 2026-10-25. A trial that one register cites in the other is shown once. Organisation-level data only: investigators, contact persons and site names are not stored, and a sponsor that could be a private person is withheld. Sponsor-to-website matches are made by name and can be wrong; check the register before relying on a record. Independent of the NLM, NIH and EMA.
Cite as: Arcadium Data, "Eli Lilly and Company clinical trials: 235 open, 561 in phase 3", https://arcadiumdata.io/clinical-trials/sponsor/lilly-com/, data as of 2026-10-25.